News Archive

SD Research Program Launched and Scientific Advisory Board Appointed

More...


The National Spasmodic Dysphonia Association announced its new research program in 2007. We had a call for research applications for new investigator startup grants or post-doctoral study on research aimed at increasing the understanding of Spasmodic Dysphonia.

These small grants will be awarded to new or established investigators in the amounts of $10,000 and $20,000 per year. This funding usually serves as "seed money" providing the funds needed for preliminary data before generating even greater funding from the National Institutes of Health.

The recipient(s) will be announced after the grants are reviewed and ranked by the new NSDA Scientific Advisory Board and then funding is approved by the Board of Directors. We were pleased to receive quality applications this first round and hope to distribute $50,000 this inaugural year.

To assist in the implementation of the new research program, the NSDA has established a new Scientific Advisory Board.

The Board is charged with:

  • Reviewing the research grants on an annual basis and making recommendations for funding to the NSDA Board of Directors;
  • Advising the NSDA Board of Directors as to the state of research in Spasmodic Dysphonia including what directions should be pursued and possible mechanisms that could be utilized;
  • Stimulating interest in research in SD.


In addition, the Chairperson of the Scientific Advisory Board will serve as chief advisor to the NSDA on all research matters that would further the goals and purposes of the Association and call meetings of the Advisory Board at his/her discretion or upon request of the NSDA Executive Committee.

The following people have agreed to serve on the Scientific Advisory Board:

Christy Ludlow, Ph.D., Chair
National Institutes of Neurological Disorders and Stroke, NIH, Bethesda, MD

Gerald Berke, M.D.
UCLA, Los Angeles, CA

Craig Evinger, Ph.D.
SUNY Stony Brook, Stony Brook, NY

Chris Sapienza, Ph.D.
University of Florida, Gainesville, FL

Carlie Tanner, Ph.D.
Parkinson's Disease Institute, Sunnyvale, CA

This is a major step forward for the NSDA and for the understanding of Spasmodic Dysphonia.

CEU Course Available on Spasmodic Dysphonia

More...

The National Spasmodic Dysphonia Association is pleased to announce its collaboration with WE MOVE on a case study entitled Case Study: The Use of Botulinum Toxin in the Treatment of Spasmodic Dysphonia as part of their initiative The Role of Chemodenervation in the Management of Hyperkinetic Movement Disorders. This case, in addition to four exercises on the foundations of chemodenervation and five other condition-specific cases, may be accessed through the WE MOVE Movement Disorder Virtual University CME Classrooms.

The case study on the use of botulinum toxin in the treatment of spasmodic dysphonia examines the different types of SD, the tools used in the assessment of this condition and the commonly employed doses of botulinum toxin type A in the treatment of adductor-type spasmodic dysphonia. The case was authored by Stephen Bansberg, M.D. Assistant Professor of Otolaryngology at the Mayo Clinic College of Medicine.

This activity is designated by WE MOVE for up to 1.0 hour of AMA PRATM Category 1 credit. WE MOVE gratefully acknowledges an unrestricted educational grant from Allergan, Inc., through which we are able to produce this activity and provide CME credit to physicians.

To participate in this free CME activity, log onto to the WE MOVE Movement Disorder Virtual University CME Classrooms and click on the lesson's title, linked to the activity at www.mdvu.org/classrooms/cme.

About WE MOVE
WE MOVE is a not-for-profit (501 C3) organization dedicated to educating and informing patients, professionals and the public about the latest clinical advances, management and treatment options for neurologic movement disorders. The Movement Disorder Virtual University is the healthcare professional’s source for movement disorder news, resources and educational activities.

Easier Done than Said...Living with a Broken Voice: New Book on Spasmodic Dysphonia

More...

Easier Done than Said...Living with a Broken Voice is a new book written by those who suffer from SD, and professionals who work with SD patients. It is a compendium of shared experiences from within the SD community.

This book is designed to:

• Provide comfort and guidance to those who are struggling to understand spasmodic dysphonia;

• Explain to family, friends, co-workers, and other interested parties the challenges faced by people with spasmodic dysphonia; and

• Bring spasmodic dysphonia to the general public’s attention.

For those who have been coping with SD for years, we hope this book will provide you with some new ideas to address current issues you might be facing. For those who are recently diagnosed or who are still seeking answers to this strange ailment, we hope this book will serve as a useful reference guide as you begin your journey through life with SD. For friends, family members, or co-workers of those with SD, we hope this book will help you to better understand the plight of people dealing with SD.

Author Karen Feeley has been living with SD since 1997 and has been an active member of the NSDA since 2001.


Emily Lim finds her Voice through Writing

More...

Congratulations to NSDA Member Emily Lim who recently published a new children's book entitled The Prince and Pauper Bear. Emily shared, "This story was inspired by my personal struggles of coping with Spasmodic Dysphonia for the past nine years."

The Prince Bear and Pauper Bear is the first story I have ever written. There are parts of me in the wo main characters. Prince Bear was me before I was stricken with the condition, while Pauper Bear resembles me after. Like me, Pauper Bear discovers goodness and kindness from different people and is given a second chance," she said.

Wanting to repay the support and kindness she has received, Emily decided to pay it forward. She has generously donated a limited quantity of her book to the NSDA with proceeds supporting the organization. Click here to order it.

Safety Issues Regarding Botulinum Toxin

More...

NSDA is aware of recent publicity generated by an FDA report and a subsequent petition from an organization called Public Citizen.

We have asked Andy Blitzer, M.D. on our NSDA Medical Advisory Board for his comments from a perspective of how this petition relates to the use of botulinum toxin as a treatment for spasmodic dysphonia. Here is what he had to say:

"The review referred to was done for all botulinum toxins (not just Botox). It was not started because of some new complications just recognized, nor a series of bad results.

The side effects and risk factors mentioned are consistent with the current U.S. labeling for BOTOX(R) and BOTOX(R) Cosmetic approved by the FDA.

Furthermore, as part of its effort to provide critical guidance to physicians and the public on the effects and use of drugs, the FDA recently completed a routine safety report on BOTOX(R) in which it reviewed serious adverse events reported to the FDA through the MedWatch system over the course of more than a decade of BOTOX(R) use, and non-serious adverse events over a year. The FDA's report reaffirmed the safety profile of BOTOX(R), noting that the majority of adverse events reviewed were included in the labeling for BOTOX(R) and BOTOX(R) Cosmetic. Of the few reported adverse events that are not included in the product labeling, none indicated a pattern suggesting a common causal relationship to BOTOX(R) and BOTOX(R) Cosmetic.

The FDA's report is consistent with information received by Allergan's own stringent post-marketing pharmacovigilance program and with our understanding of the safety profile of BOTOX(R) and BOTOX(R) Cosmetic as demonstrated in clinical trials involving more than 10,000 patients, and in clinical practice.

In addition, I think your members might want to know that this is now my 25th year of injecting all sorts of neurologic conditions with Botox (including SD). We have injected literally thousands of people with very few adverse events. This is a better safety profile than most of the other drugs that we commonly use. I hope this information helps your membership."

(From Dr Andrew Blitzer, MD, DDS
Professor of Clinical Otolaryngology
Columbia University
Director, NY Center for Voice and Swallowing Disorders

NSDA recommends that patients follow the usual practice of making a personal decision based on a discussion of their individual case and the related medical treatment with their own doctor.